Finance

Lists
LH:NYSE
Labcorp Holdings Inc
USD 366,57
+0,90%
(+3,27) 1D
USD 366,57
0,00% (0,00)
After hours
Closed: 6 Nov., 16:00:04 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LH...
Open
USD 357,25
High
USD 369,06
Low
USD 355,63
Mkt. cap
29,77 mjd
Avg. vol.
741,31 k
Volume
610,11 k
Dividend
0,79%
Quarterly dividend
USD 0,72
Ex-dividend date
29 Mei 2026
P/E ratio
30,06
52-wk high
USD 371,00
52-wk low
USD 244,52
EPS
USD 12,19
Beta
0,87
Shares outstanding
81,20 m
No. of employees
71 k
Open
USD 357,25
High
USD 369,06
Low
USD 355,63
Mkt. cap
29,77 mjd
Avg. vol.
741,31 k
Volume
610,11 k
Dividend
0,79%
Quarterly dividend
USD 0,72
Ex-dividend date
29 Mei 2026
P/E ratio
30,06
52-wk high
USD 371,00
52-wk low
USD 244,52
EPS
USD 12,19
Beta
0,87
Shares outstanding
81,20 m
No. of employees
71 k
News stories
From web sources and news partners
Profile
Labcorp Holdings Inc., operating under the brand name Labcorp, headquartered in Burlington, North Carolina, provides laboratory services used for diagnosis and healthcare decisions. It operates one of the largest clinical laboratory networks in the world and has operations in over 100 countries; although its operations are primarily in the U.S. Its Diagnostics Laboratories segment operates 2,000 patient service centers with more than 6,000 in-office phlebotomists in the United States. In addition to healthcare testing such as oncology testing, human immunodeficiency virus genotyping and phenotyping, it provides testing for: employment, DNA testing to determine parentage and to determine immigration eligibility, environmental issues, wellness, toxicology, pain management, and medical drug monitoring. It also provides 50 tests that patients can complete at home. It processes over 160 million tests per year. Approximately 10% of this segment’s revenue are from the U.S. Medicare health insurance program. Wikipedia
About Labcorp Holdings Inc
CEOAdam H. Schechter
Employees71 k
Founded1978
HeadquartersBurlington, Noord-Carolina, Verenigde State van Amerika
SectorHealth Care
IndustryHealth care provider
Analyst ratings
Based on 14 analysts giving stock ratings to LH in the past 3 months
Strong buy
Buy
11
Hold
3
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for LH in the last 3 months.
Highest
Current USD 366,57
USD 420,00 (+14,58%)
Average
USD 387,18 (+5,62%)
Lowest
USD 340,00 (-7,25%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
HSBC
Buy
Upgraded
USD 410,00
+11,8%
11/05/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
USD 400,00
+9,1%
11/04/2026
David Westenberg
Piper Sandler
Hold
Maintained
USD 365,00
-0,4%
10/30/2026
David S Macdonald
Truist Financial
Buy
Maintained
USD 395,00
+7,8%
10/29/2026
Lu Li
Bank of America Securities
Buy
Reiterated
-
-
10/29/2026
Pito Chickering
Deutsche Bank
Hold
Maintained
USD 355,00
-3,2%
10/29/2026
Kevin Caliendo
UBS
Buy
Reiterated
USD 420,00
+14,6%
10/29/2026
Erin Wright
Morgan Stanley
Buy
Reiterated
USD 388,00
+5,8%
10/30/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
USD 396,00
+8%
10/29/2026
Luke Sergott
Barclays
Hold
Maintained
USD 380,00
+3,7%
10/28/2026
Michael Cherny
Leerink Partners
Buy
Reiterated
USD 410,00
+11,8%
10/29/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
USD 340,00
-7,2%
09/11/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
09/11/2026
Lisa Gill
J.P. Morgan
Buy
Maintained
-
-
08/26/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
USD 360,00
-1,8%
07/30/2026
David Toung
Argus Research
Buy
Maintained
USD 310,00
-15,4%
06/02/2026
Unknown Analyst
Mizuho Securities
Buy
Reiterated
USD 320,00
-12,7%
05/27/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
04/30/2026
Last report
28 Okt. 2026
Fiscal period
Q3 2026
USD 4,78 / USD 4,64
+2,94%beat
Revenue / Est. (USD)
3,81 mjd / 3,76 mjd
+1,35%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
3,52 mjd
3,54 mjd
3,73 mjd
3,81 mjd
Cost of goods sold
2,52 mjd
2,52 mjd
2,62 mjd
2,70 mjd
Cost of revenue
2,52 mjd
2,52 mjd
2,62 mjd
2,70 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
549,70 m
551,00 m
577,20 m
611,40 m
Operating expense
622,30 m
626,60 m
655,30 m
692,60 m
Total operating expenses
3,14 mjd
3,15 mjd
3,27 mjd
3,39 mjd
Operating income
370,90 m
387,20 m
456,70 m
415,50 m
Other non operating income
1,90 m
-600,00 k
-3,50 m
-5,40 m
EBT including unusual items
190,60 m
319,70 m
386,40 m
328,00 m
EBT excluding unusual items
315,20 m
333,20 m
391,50 m
341,40 m
Income tax expense
25,70 m
41,70 m
87,30 m
64,90 m
Effective tax rate
13,48%
13,04%
22,59%
19,79%
Other operating expenses
-
-
-
2,50 m
Net income
164,70 m
277,80 m
298,70 m
262,80 m
Net profit margin
4,68%
7,85%
8,01%
6,90%
Earnings per share
4,07
4,25
4,99
4,78
Interest and investment income
3,50 m
12,20 m
5,60 m
1,40 m
Interest expense
-55,00 m
-55,10 m
-61,10 m
-59,10 m
Net interest expenses
-51,50 m
-42,90 m
-55,50 m
-57,70 m
Depreciation and amortization charges
-
-
-
-
EBITDA
549,40 m
560,50 m
635,70 m
598,50 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google-programme